These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11222567)

  • 1. Characterization of high-level fluoroquinolone resistance in Escherichia coli O78:K80 isolated from turkeys.
    Giraud E; Leroy-Sétrin S; Flaujac G; Cloeckaert A; Dho-Moulin M; Chaslus-Dancla E
    J Antimicrob Chemother; 2001 Mar; 47(3):341-3. PubMed ID: 11222567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations.
    Wang H; Dzink-Fox JL; Chen M; Levy SB
    Antimicrob Agents Chemother; 2001 May; 45(5):1515-21. PubMed ID: 11302820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
    Chen JY; Siu LK; Chen YH; Lu PL; Ho M; Peng CF
    Microb Drug Resist; 2001; 7(1):47-53. PubMed ID: 11310803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of the AcrAB-TolC efflux pump to high-level fluoroquinolone resistance in Escherichia coli isolated from dogs and humans.
    Sato T; Yokota S; Okubo T; Ishihara K; Ueno H; Muramatsu Y; Fujii N; Tamura Y
    J Vet Med Sci; 2013 May; 75(4):407-14. PubMed ID: 23149545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of fluoroquinolone resistance in Escherichia coli isolates from food-producing animals.
    Karczmarczyk M; Martins M; Quinn T; Leonard N; Fanning S
    Appl Environ Microbiol; 2011 Oct; 77(20):7113-20. PubMed ID: 21856834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump.
    Oethinger M; Kern WV; Jellen-Ritter AS; McMurry LM; Levy SB
    Antimicrob Agents Chemother; 2000 Jan; 44(1):10-3. PubMed ID: 10602715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of mutation in the gyrA and parC genes of nalidixic-acid-resistant salmonella serotypes isolated from animals in the United Kingdom.
    Piddock LJ; Ricci V; McLaren I; Griggs DJ
    J Antimicrob Chemother; 1998 Jun; 41(6):635-41. PubMed ID: 9687102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.
    Bebear CM; Renaudin J; Charron A; Renaudin H; de Barbeyrac B; Schaeverbeke T; Bebear C
    Antimicrob Agents Chemother; 1999 Apr; 43(4):954-6. PubMed ID: 10103208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
    Nakase K; Sakuma Y; Nakaminami H; Noguchi N
    Anaerobe; 2016 Dec; 42():166-171. PubMed ID: 27793740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates.
    Tavío MM; Vila J; Ruiz J; Ruiz J; Martín-Sánchez AM; Jiménez de Anta MT
    J Antimicrob Chemother; 1999 Dec; 44(6):735-42. PubMed ID: 10590273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
    Yang J; Luo Y; Cui S; Wang W; Han L
    Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli.
    Bachoual R; Ouabdesselam S; Mory F; Lascols C; Soussy CJ; Tankovic J
    Microb Drug Resist; 2001; 7(3):257-61. PubMed ID: 11759087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of fluoroquinolone resistance among veterinary isolates of avian Escherichia coli.
    White DG; Piddock LJ; Maurer JJ; Zhao S; Ricci V; Thayer SG
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2897-9. PubMed ID: 10991884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli.
    Vila J; Ruiz J; Goñi P; De Anta MT
    Antimicrob Agents Chemother; 1996 Feb; 40(2):491-3. PubMed ID: 8834907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii.
    Navia MM; Ruiz J; Ribera A; de Anta MT; Vila J
    J Antimicrob Chemother; 1999 Dec; 44(6):743-8. PubMed ID: 10590274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.